Olema Pharmaceuticals Renames to Olema Oncology

The clinical-stage biopharmaceutical company's new corporate name took effect November 12, 2026, while its Nasdaq ticker remains OLMA.

Updated on Nov. 12, 2026 in Diseases

Bold flat-color editorial illustration of a single glass flask holding amber liquid on a navy field, evoking a clinical-stage drug developer.
Olema Pharmaceuticals changed its corporate name to Olema Oncology effective November 12, 2026, while keeping its Nasdaq ticker OLMA. AI Illustration. Upload story photo >

Olema Pharmaceuticals, Inc. changed its corporate name to Olema Oncology, Inc., effective November 12, 2026, following an amendment to its certificate of incorporation filed with the Delaware Secretary of State. The common stock continues to trade on the Nasdaq Global Select Market under the ticker symbol OLMA.

Why it matters

The rename reflects the company's focus as a clinical-stage biopharmaceutical developer, with its lead candidate palazestrant (OP-1250) in two Phase 3 trials. Existing stock certificates bearing the prior name remain valid, so shareholders do not need to take action.

The figures come from the company's corporate filing, which lists two Phase 3 trials for palazestrant and one Phase 1 study for OP-3136, with no prior-period comparison provided. The filing does not say whether the trial count or timelines will change under the new name.

The players

Olema Oncology, Inc.

Olema Oncology is a clinical-stage biopharmaceutical company formerly known as Olema Pharmaceuticals, focused on oncology drug development with palazestrant as its lead candidate.

The details

The name change was made by amending the company's Eighth Amended and Restated Certificate of Incorporation, and Delaware law required no stockholder vote to effect it. The company is headquartered in San Francisco and maintains operations in Cambridge, Massachusetts.

Timeline

  1. November 12, 2026: Corporate name change to Olema Oncology, Inc. became effective.

Health Landscape

The rename points to the company's oral estrogen receptor degrader palazestrant, which is in two Phase 3 trials, as the centerpiece of its development strategy. The shift toward oncology-branded naming signals a company whose identity now rests on this late-stage breast cancer program.

For patients with estrogen receptor-positive breast cancer, the rename itself changes nothing about current care, since palazestrant remains investigational and is still in Phase 3 testing. The company's Nasdaq ticker stays the same, so investors tracking OLMA will see no change in how the stock is listed.

The takeaway

Corporate renames can signal where a company is putting its development resources, and here the name now points directly to oncology. Readers tracking the stock or the drug pipeline should watch the Phase 3 palazestrant trials for the next meaningful milestones.

Further reading

Explore more cancer news and research for San Francisco readers following local oncology developments.

Source note: This article includes information reported by The Manila times.